Journal
CLINICAL PHARMACOKINETICS
Volume 55, Issue 10, Pages 1289-1294Publisher
ADIS INT LTD
DOI: 10.1007/s40262-016-0401-8
Keywords
-
Categories
Funding
- Pfizer, Inc.
Ask authors/readers for more resources
Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index > 40 kg/m(2)). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available